Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 42 min ago
Peer-reviewedCC BYCancer Management and Research

Association Between Prostate Volume and PI-RADS v2.1 Performance for Detecting Clinically Significant Prostate Cancer in Men in the PSA Gray Zone: A Retrospective Study

  1. 1Department of Medical College

Abstract

Qianyue Li,1,2 Yawei Zhao,2 Lei Tang,2 Junyao Zheng,1,2 Lin Li1,2 1Clinical Medical College, Shihezi University, Shihezi, Xinjiang, 832000, People’s Republic of China; 2Department of Urology, Xinjiang Production and Construction Corps Hospital, Urumqi, Xinjiang, People’s Republic of ChinaCorrespondence: Junyao Zheng, Email [email protected] Lin Li, Email [email protected]: To evaluate prostate volume (PV) alongside PI-RADS v2.1 for predicting prostate cancer (PCa) and clinically significant prostate cancer (csPCa), and to explore whether PV was associated with PI-RADS performance in men in the PSA gray zone (4– 10 ng/mL).Methods: This retrospective study included 97 men who underwent pre-biopsy multiparametric MRI and pathological evaluation. PI-RADS performance was assessed overall and across PV strata. Two models were evaluated: Model A (PI-RADS, PV, age, and free-to-total PSA ratio) and Model B (PI-RADS, PSA density, age, and free-to-total PSA ratio). ROC analysis, DeLong tests, Firth penalized logistic regression incorporating a PI-RADS × PV interaction term, and bootstrap-corrected calibration were performed.Results: PCa and csPCa were identified in 26 (26.8%) and 23 (23.7%) patients, respectively. For csPCa, PI-RADS ≥ 4 yielded a sensitivity of 73.9% (95% CI, 51.6– 89.8%) and specificity of 77.0% (95% CI, 65.8– 86.0%); PI-RADS ≥ 5 increased specificity to 89.2% (95% CI, 79.8– 95.2%) but reduced sensitivity to 47.8% (95% CI, 26.8– 69.4%). PCa and csPCa detection rates decreased across increasing PV categories (P for trend = 0.017 and 0.014, respectively), although the subgroup estimates were imprecise. Compared with PI-RADS alone, Model A showed higher discrimination for PCa (AUC, 0.809 vs 0.721; P = 0.021) and csPCa (AUC, 0.853 vs 0.770; P = 0.015). Model B yielded AUCs of 0.805 and 0.843, respectively, but its improvements over PI-RADS alone were borderline (P = 0.050 and 0.051). The PI-RADS × PV interaction was associated with csPCa (OR, 1.025; 95% CI, 1.002– 1.055). Bootstrap-corrected mean absolute errors were 0.037 for PCa and 0.039 for csPCa.Conclusion: A model incorporating PV, age, and free-to-total PSA ratio alongside PI-RADS showed greater discrimination than PI-RADS alone in this cohort. The exploratory interaction suggests that the association between PI-RADS and csPCa may vary according to PV. External validation is required before clinical implementation.Keywords: prostate cancer, clinically significant prostate cancer, PI-RADS v2.1, prostate volume, PSA density, PSA gray zone

Related

  1. Validation of the discriminatory performance of the iPREFACE score for clinically significant fetal acidemia: an outcome-enriched nested case–control study
    Ayumu Ito, Mio Kamiya, Eijiro Hayata +2
    AJOG global reportsPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Diagnostic Performance of Triglyceride-Glucose Body Mass Index (TyG-BMI), Fibrosis-4 Index (FIB-4), and Their Combined Model for Clinically Significant Liver Fibrosis in Type 2 Diabetes Mellitus
    Tahseer Khan, Syeda Batool Tirmizi, Aamir Shehzad +4
    CureusPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  3. Joint association of the triglyceride–glucose index and central obesity with clinically significant coronary artery calcification in asymptomatic adults
    Chun-Li Wang, Chiann-Yi Hsu, Chia-Yen Lin
    Annals of MedicinePeer-reviewedCC BYFull textGeneral medicineDOAJ
  4. Diagnostic performance of the ECG-SMART AI score for detecting angiographically significant coronary artery disease in patients undergoing elective coronary angiography
    Dania A. Bani Hani, Jafar A. Alshraideh, Hamza Alduraidi +7
    PLOS Digital HealthPeer-reviewedCC BY 4.0Full textCardiovascular medicineMedical imaging & radiologyPLOS
  5. Characterization and Antimicrobial Susceptibility Patterns of Clinically Significant Non-fermenting Gram-Negative Bacilli Isolated From Clinical Specimens
    Dhanashree R Chavan, Ravindra V Shinde, Satish R Patil
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{li2026association,
  title = {{Association Between Prostate Volume and PI-RADS v2.1 Performance for Detecting Clinically Significant Prostate Cancer in Men in the PSA Gray Zone: A Retrospective Study}},
  author = {Li Q and Zhao Y and Tang L and Zheng J and Li L},
  journal = {Cancer Management and Research},
  year = {2026},
  month = nov,
  url = {https://www.dovepress.com/association-between-prostate-volume-and-pi-rads-v21-performance-for-de-peer-reviewed-fulltext-article-CMAR},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Association Between Prostate Volume and PI-RADS v2.1 Performance for Detecting Clinically Significant Prostate Cancer in Men in the PSA Gray Zone: A Retrospective Study
AU  - Li Q
AU  - Zhao Y
AU  - Tang L
AU  - Zheng J
AU  - Li L
PY  - 2026
DA  - 2026/11/15
JO  - Cancer Management and Research
UR  - https://www.dovepress.com/association-between-prostate-volume-and-pi-rads-v21-performance-for-de-peer-reviewed-fulltext-article-CMAR
AB  - Qianyue Li,1,2 Yawei Zhao,2 Lei Tang,2 Junyao Zheng,1,2 Lin Li1,2 1Clinical Medical College, Shihezi University, Shihezi, Xinjiang, 832000, People’s Republic of China; 2Department of Urology, Xinjiang Production and Construction Corps Hospital, Urumqi, Xinjiang, People’s Republic of ChinaCorrespondence: Junyao Zheng, Email [email protected] Lin Li, Email [email protected]: To evaluate prostate volume (PV) alongside PI-RADS v2.1 for predicting prostate cancer (PCa) and clinically significant prostate cancer (csPCa), and to explore whether PV was associated with PI-RADS performance in men in the PSA gray zone (4– 10 ng/mL).Methods: This retrospective study included 97 men who underwent pre-biopsy multiparametric MRI and pathological evaluation. PI-RADS performance was assessed overall and across PV strata. Two models were evaluated: Model A (PI-RADS, PV, age, and free-to-total PSA ratio) and Model B (PI-RADS, PSA density, age, and free-to-total PSA ratio). ROC analysis, DeLong tests, Firth penalized logistic regression incorporating a PI-RADS × PV interaction term, and bootstrap-corrected calibration were performed.Results: PCa and csPCa were identified in 26 (26.8%) and 23 (23.7%) patients, respectively. For csPCa, PI-RADS ≥ 4 yielded a sensitivity of 73.9% (95% CI, 51.6– 89.8%) and specificity of 77.0% (95% CI, 65.8– 86.0%); PI-RADS ≥ 5 increased specificity to 89.2% (95% CI, 79.8– 95.2%) but reduced sensitivity to 47.8% (95% CI, 26.8– 69.4%). PCa and csPCa detection rates decreased across increasing PV categories (P for trend = 0.017 and 0.014, respectively), although the subgroup estimates were imprecise. Compared with PI-RADS alone, Model A showed higher discrimination for PCa (AUC, 0.809 vs 0.721; P = 0.021) and csPCa (AUC, 0.853 vs 0.770; P = 0.015). Model B yielded AUCs of 0.805 and 0.843, respectively, but its improvements over PI-RADS alone were borderline (P = 0.050 and 0.051). The PI-RADS × PV interaction was associated with csPCa (OR, 1.025; 95% CI, 1.002– 1.055). Bootstrap-corrected mean absolute errors were 0.037 for PCa and 0.039 for csPCa.Conclusion: A model incorporating PV, age, and free-to-total PSA ratio alongside PI-RADS showed greater discrimination than PI-RADS alone in this cohort. The exploratory interaction suggests that the association between PI-RADS and csPCa may vary according to PV. External validation is required before clinical implementation.Keywords: prostate cancer, clinically significant prostate cancer, PI-RADS v2.1, prostate volume, PSA density, PSA gray zone
SN  - 1179-1322
ER  -